Erasca Inc. reports second-quarter results Thursday, with investors focused less on the clinical-stage biotech’s expected losses and more on updates surrounding its pan-RAS cancer drug that has drawn enthusiastic backing from Wall Street analysts.
international
Be The Investor Research
Read Original Source (Investing)
Erasca earnings on deck: Can pipeline progress offset losses?
Erasca Inc. reports second-quarter results Thursday, with investors focused less on the clinical-stage biotech’s expected losses and more on updates surrounding its pan-RAS cancer drug that has drawn enthusiastic backing from Wall Street analysts.